journal
https://read.qxmd.com/read/37245523/children-deserve-simple-short-safe-and-effective-treatment-for-rifampicin-resistant-tuberculosis
#1
JOURNAL ARTICLE
Anthony J Garcia-Prats, Graeme Hoddinott, Pauline Howell, Jennifer Hughes, Patrick Jean-Philippe, Soyeon Kim, Megan Palmer, H Simon Schaaf, James A Seddon, Elin Svensson, Anneke C Hesseling
No abstract text is available yet for this article.
May 25, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37244273/correction-to-lancet-infect-dis-2023-published-online-may-4-https-doi-org-10-1016-s1473-3099-23-00121-4
#2
(no author information available yet)
No abstract text is available yet for this article.
May 24, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37236222/tafenoquine-and-artemisinin-based-combination-therapy-for-vivax-malaria-end-of-the-road-or-just-the-beginning
#3
JOURNAL ARTICLE
Kamala Thriemer, Robert J Commons
No abstract text is available yet for this article.
May 23, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37236221/tafenoquine-co-administered-with-dihydroartemisinin-piperaquine-for-the-radical-cure-of-plasmodium-vivax-malaria-inspector-a-randomised-placebo-controlled-efficacy-and-safety-study
#4
JOURNAL ARTICLE
Inge Sutanto, Amin Soebandrio, Lenny L Ekawati, Krisin Chand, Rintis Noviyanti, Ari Winasti Satyagraha, Decy Subekti, Yulia Widya Santy, Chelzie Crenna-Darusallam, Instiaty Instiaty, Waras Budiman, Catur Bidik Prasetya, Soroy Lardo, Iqbal Elyazar, Stephan Duparc, Eve Cedar, Katie Rolfe, Disala Fernando, Alessandro Berni, Siôn Jones, Jörg-Peter Kleim, Kim Fletcher, Hema Sharma, Ana Martin, Maxine Taylor, Navin Goyal, Justin A Green, Lionel K Tan, J Kevin Baird
BACKGROUND: Tafenoquine, co-administered with chloroquine, is approved for the radical cure (prevention of relapse) of Plasmodium vivax malaria. In areas of chloroquine resistance, artemisinin-based combination therapies are used to treat malaria. This study aimed to evaluate tafenoquine plus the artemisinin-based combination therapy dihydroartemisinin-piperaquine for the radical cure of P vivax malaria. METHODS: In this double-blind, double-dummy, parallel group study, glucose-6-phosphate dehydrogenase-normal Indonesian soldiers with microscopically confirmed P vivax malaria were randomly assigned by means of a computer-generated randomisation schedule (1:1:1) to dihydroartemisinin-piperaquine alone, dihydroartemisinin-piperaquine plus a masked single 300-mg dose of tafenoquine, or dihydroartemisinin-piperaquine plus 14 days of primaquine (15 mg)...
May 23, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37236220/highly-multidrug-resistant-gram-negative-bacterial-infections-in-war-victims-in-ukraine-2022
#5
LETTER
Oskar Ljungquist, Oleksandr Nazarchuk, Gunnar Kahlmeter, Vigith Andrews, Thalea Koithan, Lisa Wasserstrom, Dmytro Dmytriiev, Nadiia Fomina, Vira Bebyk, Erika Matuschek, Kristian Riesbeck
No abstract text is available yet for this article.
May 23, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37230106/use-of-point-of-care-biomarkers-to-reduce-antibiotic-resistance
#6
JOURNAL ARTICLE
David S C Hui
No abstract text is available yet for this article.
May 22, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37230105/implementation-of-point-of-care-testing-of-c-reactive-protein-concentrations-to-improve-antibiotic-targeting-in-respiratory-illness-in-vietnamese-primary-care-a-pragmatic-cluster-randomised-controlled-trial
#7
JOURNAL ARTICLE
Nga Thi Thuy Do, Tien Viet Dung Vu, Rachel C Greer, Sabine Dittrich, Maida Vandendorpe, Ngoc Thach Pham, Dieu Ngan Ta, Hung Thai Cao, Thanh Vinh Khuong, Thi Bich Thuy Le, Thanh Huyen Duong, Thanh Ha Nguyen, Ngoc Thien Huong Cai, Thi Quynh Trang Nguyen, Son Tung Trinh, H Rogier van Doorn, Yoel Lubell, Sonia Lewycka
BACKGROUND: In previous trials, point-of-care testing of C-reactive protein (CRP) concentrations safely reduced antibiotic use in non-severe acute respiratory infections in primary care. However, these trials were done in a research-oriented context with close support from research staff, which could have influenced prescribing practices. To better inform the potential for scaling up point-of-care testing of CRP in respiratory infections, we aimed to do a pragmatic trial of the intervention in a routine care setting...
May 22, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37216959/cs-2034-mrna-vaccine-a-new-option-for-covid-19-infection
#8
JOURNAL ARTICLE
Ruiqi Zhang, Ivan Fan-Ngai Hung
No abstract text is available yet for this article.
May 19, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37216958/safety-immunogenicity-and-efficacy-of-the-mrna-vaccine-cs-2034-as-a-heterologous-booster-versus-homologous-booster-with-bbibp-corv-in-adults-aged-%C3%A2-18-years-a-randomised-double-blind-phase-2b-trial
#9
JOURNAL ARTICLE
Jun-Dong Wu, Jing-Xin Li, Jian Liu, Hao-Meng Wang, Guang-Hui Zhou, Jin Li, Dou Wu, Xiang Chen, Yan Feng, Xiao-Yuan Qi, Xue Wang, Jin-Bo Gou, Tie-Liang Ma, Xiao-Yun Yang, Li-Feng Xu, Peng Wan, Tao Zhu, Zhong-Fang Wang, Feng-Cai Zhu
BACKGROUND: Heterologous boosting is suggested to be of use in populations who have received inactivated COVID-19 vaccines. We aimed to assess the safety and immunogenicity of a heterologous vaccination with the mRNA vaccine CS-2034 versus the inactivated BBIBP-CorV as a fourth dose, as well as the efficacy against the SARS-CoV-2 omicron (BA.5) variant. METHODS: This trial contains a randomised, double-blind, parallel-controlled study in healthy participants aged 18 years or older (group A) and an open-label cohort in participants 60 years and older (group B), who had received three doses of inactivated whole-virion vaccines at least 6 months before enrolment...
May 19, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37209708/engaging-pharmacists-and-medicine-vendors-in-antimicrobial-stewardship-in-lmics
#10
LETTER
Charity Oga-Omenka, Ukamaka Okafor, Giorgia Sulis
No abstract text is available yet for this article.
May 17, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37207687/tracheobronchial-tuberculosis-and-its-sequelae-in-children-and-adolescents
#11
LETTER
Ming-Jin Yang, Jian-Qing He, Shu-Liang Guo
No abstract text is available yet for this article.
May 16, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37201548/correction-to-lancet-infect-dis-2023-published-online-https-doi-org-10-1016-s1473-3099-22-00877-5
#12
(no author information available yet)
No abstract text is available yet for this article.
May 15, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37182534/efficacy-and-safety-of-sulbactam-durlobactam-versus-colistin-for-the-treatment-of-patients-with-serious-infections-caused-by-acinetobacter-baumannii-calcoaceticus-complex-a-multicentre-randomised-active-controlled-phase-3-non-inferiority-clinical-trial-attack
#13
JOURNAL ARTICLE
Keith S Kaye, Andrew F Shorr, Richard G Wunderink, Bin Du, Gabrielle E Poirier, Khurram Rana, Alita Miller, Drew Lewis, John O'Donnell, Lan Chen, Harald Reinhart, Subasree Srinivasan, Robin Isaacs, David Altarac
BACKGROUND: An urgent need exists for antibiotics to treat infections caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (ABC). Sulbactam-durlobactam is a β-lactam-β-lactamase inhibitor combination with activity against Acinetobacter, including multidrug-resistant strains. In a phase 3, pathogen-specific, randomised controlled trial, we compared the efficacy and safety of sulbactam-durlobactam versus colistin, both in combination with imipenem-cilastatin as background therapy, in patients with serious infections caused by carbapenem-resistant ABC...
May 11, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37182533/treating-carbapenem-resistant-acinetobacter-baumannii-infections
#14
JOURNAL ARTICLE
Maddalena Giannella, Pierluigi Viale
No abstract text is available yet for this article.
May 11, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37178707/the-dangers-of-using-large-language-models-for-peer-review
#15
LETTER
Tjibbe Donker
No abstract text is available yet for this article.
May 10, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37178706/immunogenicity-of-novel-oral-poliovirus-vaccine-type-2-administered-concomitantly-with-bivalent-oral-poliovirus-vaccine-an-open-label-non-inferiority-randomised-controlled-trial
#16
JOURNAL ARTICLE
Amanda L Wilkinson, Khalequ Zaman, Masuma Hoque, Concepcion F Estivariz, Cara C Burns, Jennifer L Konopka-Anstadt, Bernardo A Mainou, Stephanie D Kovacs, Qian An, Jacquelyn S Lickness, Mohammad Yunus, Cynthia J Snider, Yiting Zhang, Elizabeth Coffee, Talha Abid, Steven G F Wassilak, Mark A Pallansch, M Steven Oberste, John F Vertefeuille, Abhijeet Anand
BACKGROUND: Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine-derived poliovirus type 2 outbreaks. Bivalent oral poliovirus vaccine (bOPV; containing Sabin types 1 and 3) is the vaccine of choice for type 1 and type 3 outbreak responses. We aimed to assess immunological interference between nOPV2 and bOPV when administered concomitantly. METHODS: We conducted an open-label, non-inferiority, randomised, controlled trial at two clinical trial sites in Dhaka, Bangladesh...
May 10, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37178705/polio-endgame-complexity-updating-expectations-for-nopv2
#17
JOURNAL ARTICLE
Kimberly M Thompson
No abstract text is available yet for this article.
May 10, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37156259/highlights-from-eccmid-2023
#18
JOURNAL ARTICLE
Marco De Ambrogi
No abstract text is available yet for this article.
May 5, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37156258/prevention-of-long-covid-progress-and-challenges
#19
JOURNAL ARTICLE
Ziyad Al-Aly
No abstract text is available yet for this article.
May 5, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37150186/lessons-from-covid-19-for-rescalable-data-collection
#20
REVIEW
Sangeeta Bhatia, Natsuko Imai, Oliver J Watson, Auss Abbood, Philip Abdelmalik, Thijs Cornelissen, Stéphane Ghozzi, Britta Lassmann, Radhika Nagesh, Manon L Ragonnet-Cronin, Johannes Christof Schnitzler, Moritz Ug Kraemer, Simon Cauchemez, Pierre Nouvellet, Anne Cori
Novel data and analyses have had an important role in informing the public health response to the COVID-19 pandemic. Existing surveillance systems were scaled up, and in some instances new systems were developed to meet the challenges posed by the magnitude of the pandemic. We describe the routine and novel data that were used to address urgent public health questions during the pandemic, underscore the challenges in sustainability and equity in data generation, and highlight key lessons learnt for designing scalable data collection systems to support decision making during a public health crisis...
May 4, 2023: Lancet Infectious Diseases
journal
journal
20187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.